Replies to post #1470 on BioNeutral Group Inc. (fka BONU)

[StockWatcher]

YOU ARE DEAD ON King Koopa! BONU GOING MUCH HIGHER SOON ENOUGH!

As I stated earlier, I was trying to reach the company and did, and we are GOLDEN here on a very large scale.

What I was told was the very things listed here. Since the information that was discussed and confirmed is posted in the 10Q, the best thing that I can say is the relationships they have are with some of the BIGGEST Pharmas in the industry!

You can figure out the rest from there.

But what I can and will stress is this statement.

To date our marketing efforts have led to over 100 trials of our products of which 70 are active at the current time. Our products have been ordered within the segments of university laboratory medical research, pharmaceutical manufacturing and veterinarian care. These trials have led to the addition of 20 new customers of our products. The 70 active trials currently in process are pending results for placement of orders.

All I can say is that some of these trials are more than likely no longer trials and are now paying customers! When we hear about the new customers and their updated revenue numbers I think we will all see the writing on the wall here.

IMHO, BONU will not be below .10 in the near term.

king koopa said: some excerpts on ongoing and future operations from the recent 10Q, very good stuff for BONU shareholders some highlights bolded below:


Currently, we are focusing our efforts on the commercialization of a Ygiene ® formulation for healthcare and industrial applications. Some of our potential customers that operate in the healthcare marketplace require product testing and trials before purchasing our products. We have retained four professional sales persons with experience selling specialty chemicals such as ours. In doing so, we are investing our resources in their process to market and sell our products. We are developing our Ogiene ® products to potentially eliminate or reduce odors of many chemicals such as hydrogen sulfide, formaldehyde and ammonia, and to reduce certain green­house gases such as carbon dioxide and sulfur dioxide. Our Ogiene ® formulations are designed to interact with the functional organic or inorganic groups of harmful gases and reduce or eliminate them.

In calendar year 2013 we initiated our commercialization strategy to sell our products into the healthcare and life sciences markets, and also into industrial markets. Within healthcare and life sciences, most of our customer’s perform trial testing of our products prior to purchasing which can significantly lengthen the selling cycle. To date our marketing efforts have led to over 100 trials of our products of which 70 are active at the current time. Our products have been ordered within the segments of university laboratory medical research, pharmaceutical manufacturing and veterinarian care. These trials have led to the addition of 20 new customers of our products. The 70 active trials currently in process are pending results for placement of orders.


Our initial commercialization strategy, which was utilized as a basis for our 2012 impairment testing, contained a forecast that called for material sales to begin to occur in April of 2013. However, primarily due to the lead time involved with the following activities: 1) sales force orientation and training; 2) production of selling materials and 3) a relatively long sales cycle that includes product trial testing, we have lowered our 2013 revenue forecast to $1,120,000. We forecast to make up the difference between our original forecast and our current forecast in calendar years 2014 and 2015, and the effect of our revision is not anticipated to have a significant impact on our valuation.

[stervc]

BONU .03+ Fundamental Valuation…

Let’s consider the confirmation of the Outstanding Shares (OS) for BONU to still be 164,616,730 shares as recently confirmed below:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92974228
http://www.otcmarkets.com/stock/BONU/company-info

Let’s consider that fact that BONU downgraded its 2013 Revenues to be $1,120,000 as the company indicated within their most recent 10Q filed with the SEC:

http://www.sec.gov/Archives/edgar/data/1427030/000121390013005105/f10q0713_bioneutralgroup.htm
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9510639
Our initial commercialization strategy, which was utilized as a basis for our 2012 impairment testing, contained a forecast that called for material sales to begin to occur in April of 2013. However, primarily due to the lead time involved with the following activities: 1) sales force orientation and training; 2) production of selling materials and 3) a relatively long sales cycle that includes product trial testing, we have lowered our 2013 revenue forecast to $1,120,000. We forecast to make up the difference between our original forecast and our current forecast in calendar years 2014 and 2015, and the effect of our revision is not anticipated to have a significant impact on our valuation. …

Let’s presume that with their manufacturing agreements in place that there is a 75% Net Expense Margin for 2013 which in-turn will return a 25% Net Income/Profit Margin for BONU for 2013… then see below:

$1,120,000 BONU 2013 Revenues x .25 Net Profit Margin = $280,000 “Potential” Net Income

$280,000 ÷ 164,616,730 (OS) = .0017 “Potential” EPS

(EPS = Earnings Per Share)

Within the link below is confirmation that the Price to Earnings (P/E) Ratio is 19.40 for the Chemicals - Major Diversified Industry which is the Industry of where BONU should exist to trade so we should use such as its growth multiple as indicated below:
http://biz.yahoo.com/p/110conameu.html

.0017 “Potential” EPS x 19.40 P/E Ratio = .0329 per share “Potential” BONU Valuation

Understand, I threw the word ”Potential” in there because still, although BONU is slowly revealing to us their plan, they still have to file such numbers above to capture what I posted above. I believe that as BONU reveals more of their business objectives to further confirm the growth as expected from what was within the same 10Q filed with the SEC, we should see some share prices much higher than the .0329 that I had derived above for the reasons below:

http://www.sec.gov/Archives/edgar/data/1427030/000121390013005105/f10q0713_bioneutralgroup.htm
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9510639
In calendar year 2013 we initiated our commercialization strategy to sell our products into the healthcare and life sciences markets, and also into industrial markets. Within healthcare and life sciences, most of our customer’s perform trial testing of our products prior to purchasing which can significantly lengthen the selling cycle. To date our marketing efforts have led to over 100 trials of our products of which 70 are active at the current time. Our products have been ordered within the segments of university laboratory medical research, pharmaceutical manufacturing and veterinarian care. These trials have led to the addition of 20 new customers of our products. The 70 active trials currently in process are pending results for placement of orders.

BONU DD to read for newcomers:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93021647
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92985172
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92991127
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92992761
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93020546
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93136815
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93200276
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93184863

v/r
Sterling